Centers for Disease Control and Prevention (CDC) Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Building a New Generation of Public Health Leaders Forged in a Public Health Crisis
Am J Public Health. 2024 Apr 11:e1-e7. doi: 10.2105/AJPH.2024.307633. Online ahead of print.ABSTRACTThe COVID-19 pandemic presented wide-ranging leadership challenges to public health leaders and public health organizations. In its wake, as the necessity of reconstructing public health and modernizing the Centers for Disease Control and Prevention (CDC) is considered, we reviewed reports from the Commonwealth Fund and the CDC and other leadership-focused literature to identify common themes for a new generation of public health leaders. We posit that this new generation must have the ability to communicate (build and maint...
Source: American Journal of Public Health - April 11, 2024 Category: International Medicine & Public Health Authors: Susan C Helm-Murtagh Paul C Erwin Source Type: research

Building a New Generation of Public Health Leaders Forged in a Public Health Crisis
Am J Public Health. 2024 Apr 11:e1-e7. doi: 10.2105/AJPH.2024.307633. Online ahead of print.ABSTRACTThe COVID-19 pandemic presented wide-ranging leadership challenges to public health leaders and public health organizations. In its wake, as the necessity of reconstructing public health and modernizing the Centers for Disease Control and Prevention (CDC) is considered, we reviewed reports from the Commonwealth Fund and the CDC and other leadership-focused literature to identify common themes for a new generation of public health leaders. We posit that this new generation must have the ability to communicate (build and maint...
Source: Am J Public Health - April 11, 2024 Category: International Medicine & Public Health Authors: Susan C Helm-Murtagh Paul C Erwin Source Type: research

Immunomodulators and risk for breakthrough COVID-19 after third SARS-CoV-2 mRNA vaccine among patients with rheumatoid arthritis: a cohort study
The US Centers for Disease Control and Prevention (CDC) recommends three SARS-CoV-2 messenger ribonucleic acid (mRNA) vaccine doses, rather than two, to complete the initial vaccine series for immunosuppressed patients. However, they may remain at risk for breakthrough COVID-19 due to immunomodulators that blunt vaccine responses.1 Identifying patients at highest risk for breakthrough COVID-19 can prioritise resources for prevention. Therefore, we investigated the risk of breakthrough COVID-19 among fully vaccinated patients with rheumatoid arthritis (RA) using disease-modifying antirheumatic drugs (DMARDs) and/or glucocor...
Source: Annals of the Rheumatic Diseases - April 11, 2024 Category: Rheumatology Authors: Schiff, A. E., Wang, X., Patel, N. J., Kawano, Y., Hanberg, J. L., Kowalski, E. N., Cook, C. E., Vanni, K. M., Qian, G., Bade, K. J., Saavedra, A. A., Srivatsan, S., Williams, Z. K., Venkat, R. K., Wallace, Z. S., Sparks, J. A. Tags: ARD, COVID-19 Letter Source Type: research

Assessing the Real-World Effectiveness of Immunizations for Respiratory Syncytial Virus
This Viewpoint discusses recommendations from the US Centers for Disease Control and Prevention for newly licensed immunizations for respiratory syncytial virus in infants, children with high-risk conditions, and older adults. (Source: JAMA - Journal of the American Medical Association)
Source: JAMA - Journal of the American Medical Association - April 11, 2024 Category: General Medicine Source Type: research

Immunogenicity and safety of concomitant administration of recombinant COVID-19 vaccine and quadrivalent inactivated influenza vaccine in Chinese adults: An open-label, randomized, controlled trial
Volume 20, Issue 1, December 2024 . (Source: Human Vaccines and Immunotherapeutics)
Source: Human Vaccines and Immunotherapeutics - April 11, 2024 Category: Allergy & Immunology Authors: Tao HuangJun YuSiyuan ZhangDewei TengDefang DaiYinbiao ZhuLidong Gaoa Department of Vaccine Clinical Observation Center, Hunan Provincial Center for Disease Control and Prevention, Changsha, Hunan, P.R. Chinab Jiangsu GDK Biological Technology Co, Ltd, Ta Source Type: research

Balanced on the Biggest Wave: Nirsevimab for Newborns
Neonatal Netw. 2024 Apr 1;43(2):105-115. doi: 10.1891/NN-2023-0056.ABSTRACTRespiratory syncytial virus (RSV) is the leading cause of hospitalization in infancy in the United States. Nearly all infants are infected by 2 years of age, with bronchiolitis requiring hospitalization often occurring in previously healthy children and long-term consequences of severe disease including delayed speech development and asthma. Incomplete passage of maternal immunity and a high degree of genetic variability within the virus contribute to morbidity and have also prevented successful neonatal vaccine development. Monoclonal antibodies re...
Source: Neonatal Network - April 10, 2024 Category: Perinatology & Neonatology Authors: Christopher McPherson Christine R Lockowitz Jason G Newland Source Type: research